BlueWind Medical System for the Treatment of Patients With OAB

Clinical Trial Description

BlueWind Medical system safety and performance in treatment of patients diagnosed with overactive bladder (OAB) ;

Study Design

See also
Status	Clinical Trial	Phase
Completed	`NCT01260311` - Post Marketing Surveillance Of Fesoterodine In Filipino Patients With Over Active Bladder	N/A
Completed	`NCT02186041` - Sacral Neuromodulation With InterStim® Therapy for Intractable Urinary Voiding Dysfunctions (SOUNDS): an Observational Study
Completed	`NCT01672190` - Lessening Incontinence by Learning Yoga	N/A
Completed	`NCT01318837` - A Study to Evaluate Response of Over Active Bladder Symptom Score to Solifenacin Treatment	Phase 4

See also

Status

Clinical Trial

Phase

Completed

NCT01260311 - Post Marketing Surveillance Of Fesoterodine In Filipino Patients With Over Active Bladder

N/A

Completed

NCT02186041 - Sacral Neuromodulation With InterStim® Therapy for Intractable Urinary Voiding Dysfunctions (SOUNDS): an Observational Study

Completed

NCT01672190 - Lessening Incontinence by Learning Yoga

N/A

Completed

NCT01318837 - A Study to Evaluate Response of Over Active Bladder Symptom Score to Solifenacin Treatment

Phase 4

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT02299544
Study type	Interventional
Source	Rainbow Medical
Contact
Status	Completed
Phase	N/A
Start date	February 2015
Completion date	December 2018

BlueWind Medical System for the Treatment of Patients With OAB — OAB

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms